RxDoctor Payments Data

Justin Krafft, PA

Physician Assistant · Saint Louis, MONPI 1245828904

Payments from drug & device makers

$4,051in general payments, 2019–2025

Across 152 payments — averaging $26.65 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Travere Therapeutics, Inc.$1K
  • AstraZeneca$1K
  • Vifor Pharma, Inc.$420
  • Otsuka America Pharmaceutical, Inc.$377
  • Amgen$200
  • Calliditas Therapeutics US Inc.$172
  • plus $518 from 11 others

What the payments were for

  • Speaking & faculty fees$58014%
  • Food & beverage$3,47186%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,051 in reported general payments places this provider in the 90th percentile of 1,380 physician assistant providers in Missouri.

See all physician assistant providers in Missouri

Medicare billing

Part B allowed, 2024
$66,097
Medicare patients
416
Services billed
734

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
FarxigaDapagliflozin Propanediol71$50,755
Thiola EcTiopronin12$40,458
VeltassaPatiromer Calcium Sorbitex30$31,305
LokelmaSodium Zirconium Cyclosilicate49$28,503
Potassium Citrate ErPotassium Citrate70$4,824
Torsemide136$2,304
Sevelamer Carbonate19$1,818
Nifedipine ErNifedipine42$1,460
Amlodipine Besylate179$1,410
Nebivolol Hcl18$1,248
Potassium Chloride42$1,224
Allopurinol113$949
Calcitriol71$759
Midodrine Hcl17$709
Losartan Potassium95$651

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaFarxiga, Lokelma$1,130$79,258120 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,380 physician assistant providers in Missouri.

Other physician assistant in Saint Louis

See the full list for Missouri

Where these figures come from

Is this you, or does something look wrong? →